The first and most important general observation is that the population of the 16 countries described enjoys essentially universal access to healthcare services. Some countries (the United Kingdom, Sweden, Denmark, Finland, Spain, and Italy) cover any individual living in the country. Other countries manage, through a mix of public and private funding and services, to cover close to 100 % of the population.
The second observation is the complexity and diversity of the healthcare systems of the countries described. Each country has a healthcare system that has evolved over time, with decisions based on social and cultural preferences. While trends such as population aging and increases in healthcare expenditures are common, mechanisms for dealing with these issues generally are not. Diversity may be a strength. The countries of the European Union present a series of natural experiments. They have much to learn from each other in the study of the strengths and weaknesses of other healthcare systems (including the development and use of HTA).
The healthcare systems of the 16 countries are all continuing to evolve, in a process that has come to be called "healthcare reform" (Saltman and Figueras 1979) . Healthcare reform often includes paying attention to the value for money of the healthcare system and attempts to make health care more efficient or more evidence-based. Reforming health care may mean changing the financial incentives or management structures in a particular healthcare system. It may mean new programs for dealing with an aging population. It may mean new regulations or other attempts to control or rationalize health technology.
Finally, an impetus for change in many countries is population dissatisfaction with the healthcare system. Blendon et al. (1990) has compared the levels of satisfaction to the levels of healthcare spending per capita. If Sweden is excluded from the analysis, public satisfaction in Europe is associated with higher levels of spending.
In the countries of the European Union, national HTA programs have been established during the last decade or so (Tab. 1). Leaders include Sweden and Denmark, which began to assess health technologies in the early 1970s, and the Spanish province of Catalonia, which established a Committee on Health Technology in 1984. Countries that have established or designated national programs to become i nvolved in healthcare technology assessment include Sweden (1987) , France (1990) , the United Kingdom (1990) , Spain (1994) , Finland (1995), and Denmark (1997) . In addition, regional or provincial programs have been established, especially in Spain and Italy. Some countries, such as the Netherlands and Switzerland, have extensive HTA activities. Finally, interest is growing in a number of other European Union countries, including Italy, Germany, and Greece, and in eastern European countries, including Poland, Hungary, Czech Republic, Romania, and Lithuania.
HTA is organized and implemented in a somewhat different manner in each country. One of the main determinants of such differences is the nature of the health system of the country. Some countries, such as Sweden, Spain (and several provinces, including Catalonia), and France, have an actual public agency for assessment of health technology. Others, such as the Netherlands and Switzerland, implement HTA primarily in relation to payment for health care through sickness funds and insurance companies. The United Kingdom has embedded HTA in the R&D Programmes of the National Health Service (NHS) and the Department of Health in an attempt to bring HTA into all administrative and clinical decisions. Likewise, methods differ, although countries are showing a tendency to converge in their use of methods. Sweden and France focus on synthesis of existing knowledge as their most important tool. The United Kingdom and the Netherlands also put more emphasis on commissioning prospective studies on high priority subjects. 
A tentative evaluation of HTA activities in Europe
The evaluation will be presented in the following categories: 
Functions of HTA
Use of HTA seems to be increasing in all countries in the European Union. The common use of such terms as "evidence-based medicine" indicates an orientation to use HTA results and similar information as a guide to policy and practice.
In countries that have developed HTA systems, use at the policy level is generally good, although more remains to be done. Use of HTA at the management level (hospitals, for example) seems to be limited in most countries, however, and it is widely acknowledged that clinicians have not actually changed their practice to agree with HTA results despite the rhetoric about evidence.
Doing HTA likewise has increased dramatically in a number of countries, notably the United Kingdom, Sweden, Spain, France, and the Netherlands. In other countries, HTA seems to be done more frequently than in the past. However, the volume of HTA is quite insufficient to answer the thousands of questions and to assess the thousands of technologies that need assessment.
Funding and supporting HTA is likewise growing in a number of countries. Dramatic rises in expenditures have especially been seen in the United Kingdom and the Netherlands, where the emphasis is more often on prospective research.
Steering or co-ordinating HTA has changed dramatically during the past few years, with the development of formal national and regional programs. Countries that have made obvious progress in this area include the United Kingdom, Spain, and Sweden. On the other hand, the Netherlands is one of the most active supporters of HTA in Europe, but it is only beginning to develop a basic system or coordinating structure for HTA. Switzerland also has had no co-ordinated HTA system despite considerable activity, but it too is in the process of establishing national co-ordination activities.
Supporting/promoting HTA at the policy level has likewise been seen in a number of countries. HTA does not become accepted for theoretical reasons; it is accepted because of success. As agencies and programs have carried out useful assessments, active support for HTA has grown.
Focus of HTA
It has often been said that the healthcare system is actually a "disease care system" with little activity related to health. The same could be said of HTA. The general focus of HTA until recently was on expensive, new diagnostic or therapeutic procedures, usually with expensive equipment involved. There have gradually been changes, however. In 1986 a Canadian document advocated needs-based HTA, that is, starting from the health condition instead of the technology (Feeny, Guyatt and Tugwell 1986) . This approach has become more common and is especially prominent in the United Kingdom and Sweden.
The field of prevention by screening has been comprehensively assessed, especially by the U.S. Prevention Task Force (1996) , which has stimulated increasing interest in Europe as well. In the HTA-Europe project, partners examined several preventive technologies in their respective countries, showing that prevention and screening procedures often seem to be prematurely adopted without adequate assessment.
In an era of chronic diseases, rehabilitation and supports for the disabled should become of greater concern. Technology has much to offer disabled people, but it must be assessed just as in any other area. Few such assessments have been done. Still, this too is changing.
Despite the obvious importance of old technology, indicated in statements about the lack of assessment in this area, programs still focus largely on the new technology. However, this seems to be changing. The Cochrane Collaboration has undertaken to identify and review randomized controlled clinical trials in many areas of existing practice. In the Netherlands, an extensive Delphi-like process produced a list of 126 technologies that were in common use but still needed assessment; the list was later updated to 194 candidate technologies.
HTA can deal with an individual technology, a group of related technologies, or a service or program for certain problems. The majority of assessments probably present information on one or only a few technologies, although assessments of systems are becoming more prominent.
Finally, HTA leads to recommended a ctions. Such actions have often involved regulation, and changes in payment are currently a popular option. Educational strategies are not so often proposed. Because of the limitations of formal policies, however, HTA agencies and others have attempted to develop new strategies for dissemination and implementation of HTA results (Granados, Jonsson, Banta et al. 1997) .
Type of Technology
The most assessed type of technology surely must be pharmaceuticals. Pharmaceuticals have been subject to systematic assessment for safety and efficacy for decades. A great deal of assessment information on drugs is available. On the other hand, the European system of pharmaceutical regulation does not deal with a number of important questions, such as costeffectiveness, relative efficacy, and appropriate indications. HTA agencies are being increasingly called upon to fill such gaps. In France, a new program has been established to assure comprehensive assessment of pharmaceuticals.
Medical equipment is subject to a reasonable amount of assessment, but this assessment is mainly technical, and generally does not even deal with clinical efficacy. HTA agencies haven often been involved in assessing equipment and procedures that involve equipment.
The diagnostic and therapeutic procedures of healthcare practice have been a main emphasis of HTA since its earliest beginnings. While this is appropriate and will continue, other priorities are emerging.
A field that has great potential as well as great potential costs is telematics, the applic ation of computers and communications in health care. There are literally thousands of applications of telematics possible in health care. Knowledge of the benefits and costs of telematics is only beginning to be developed. While activities have begun, the task is enormous.
Type of Healthcare Provider
As stated above, the main emphasis of HTA from its beginnings has been on expensive diagnostic and therapeutic procedures. This means that the main providers involved in HTA have been specialty physicians. They have been researchers in the field, subjects of the r esearch, and objects of attempts to change their behavior. Gradually, however, primary care and general practice have become the subject of HTA research. The Netherlands is a leader in this field.
Nurses have not been very much involved in HTA. Likewise, in dentistry, HTA has had almost no involvement or impact. Assessment is difficult in these areas because of a paucity of well-designed research studies on efficacy and safety. As mentioned already, in some other types of services, such as physiotherapy, assessment is beginning. The problem in many such areas, as with dentistry and nursing, is the relative lack of prospective research.
Level of the System
Consumers. Traditionally, the role of consumers in health care, including research and health technology assessment, has been limited. It has been recognized that this situation needs to change. The choice of a particular technology depends heavily on the interaction of the patient and the physician. Patients tend to equate quality of care with the ordering of tests or the prescription of treatment, although they are also very concerned with quality of life, while physicians sometimes emphasize more "medical concerns", such as morbidity and mortality (Banta and Luce 1993) . This implies that it is of the utmost importance to involve consumers in discussions concerning healthcare technology.
When identifying technologies in need of assessment, consumers' experiences could be of great value. In data collection and testing, consumers are often involved as subjects. With their perspectives, consumers might have a valuable input to research design. Synthesis activities might be improved by consumer i nput. And perhaps the most important consumer role could be in dissemination and implementation of HTA results. Educated consumers can react to ineffective care or cost-ineffective care, especially by demanding beneficial care. But obviously, they must have good information as a basis for such demands.
Consumers need to become partners in the HTA process. There are considerations along these lines in such countries as Sweden, the Netherlands, and the United Kingdom, but developments in general are still at an early stage.
Clinical Professionals. The primary r esponsibility of medical professionals is to provide high-quality health care to their patients. To meet this responsibility requires continual self-monitoring and improvements in care. Improving quality means applying existing and new knowledge and technologies in an appropriate manner. This has been called "evidencebased medicine".
Medical professionals and others have been active during recent years in producing clinical guidelines for this purpose. A concern related to HTA is that guidelines are generally not based on a structured review of all available scientific literature, since carrying out a structured review is time-consuming and expensive. The problem with guidelines underlines the importance of expanding synthesis activities and in co-operating in international efforts related to HTA and synthesis. Cooperation among such movements as evidencebased medicine, the Cochrane Collaboration, and HTA is becoming more and more of a priority.
Education for medical professionals is also a critical concern. In the European Union there is a "principal agreement" that all member states recognize the certificate or diploma of medical professionals. This does not mean that medical education is the same in all member states, but it must meet minimum standards. It could be beneficial if all member states i ncluded HTA and evidence-based medicine in their education for medical professionals.
Hospitals (Especially Teaching Hospitals) . Users of HTA are diverse. Hospitals are an important potential user, since they are the main purchasers of equipment and they provide the bulk of expensive, high-technology services. HTA can be used by hospitals for guiding difficult choices, especially in balancing o rganizational and community needs (Lumsdon 1992) . Hospitals are often involved in the i mplementation of HTA information. However, they have a major problem in finding reliable information, since most information comes from industry. Synthesis reports could be designed to support policy making at the hospital level.
HTA Agencies and Other Providers of HTA Information. Such organizations function to provide information. But without a system for HTA, they may not be effective. A complete system for HTA would monitor technological change at all stages of technological development and diffusion.
A system for HTA could be said to have five main tasks:
1. Identification: monitoring technologies, setting priorities; 2. Testing: data collection and analysis; 3. Synthesis: collecting and interpreting existing information; 4. Dissemination: providing HTA information to users; and 5. Implementation: helping to assure the application of HTA results.
These five tasks can be divided among several different agencies or programs. However, coordination of the tasks then becomes quite i mportant. Furthermore, methods should be matched to the problem being addressed. The EUR-ASSESS project is an example of a project working to assure a degree of standardization of methods involved in HTA (Banta 1997 It is also known that the results of HTA have not been effectively disseminated throughout the world. Effective dissemination requires contacting the potential users and convincing them of the importance and validity of the information. Use of the Internet and the World Wide Web is increasing. Direct educational activities, especially for clinical providers, are also necessary.
Industry. The industries involved in HTA are mainly the pharmaceutical industry and the medical devices industry. Industry has much to teach the rest of the healthcare system, since all drugs are assessed before they come into widespread use. Ideally, all technologies would be tested before they came into use. As pointed out earlier, however, the assessments carried out in the pharmaceutical area are actually quite limited, and access to information is also a problem.
Industry sees the present economic climate of the European Union as difficult, especially for pharmaceuticals. This situation will probably only become more restrictive. Governments are demanding more HTA information to rationalize the use of drugs and, in some cases, medical equipment. To survive in such a demanding environment, industry needs to begin HTA early in the research and development phase of a technology. Many companies have already realized this fact and are acting. The rapidly growing field of pharmacoeconomics is one manifestation of this realization.
A major problem is that developments from industry are often not related to health needs but are technologically driven. Industry could work more effectively with others, including those in HTA, to base developments on information such as burden of disease. Signif icant elements of the industry have already begun such activities.
National/Regional Government. Governments in a number of European Union countries have taken the lead in encouraging HTA through a number of actions.
A strategy for HTA as part of research policy has been developed in a number of countries. HTA needs to be approached as a bridge between clinical research and policy making. This means that scientific excellence must be coupled to societal relevance.
In some countries, a large number of organizations are involved in HTA. These o rganizations may or may not network toward a common goal. Co-operation within and b etween such organizations is needed to avoid duplication of work and to stimulate the sharing of results.
Other interesting policies that can be linked to HTA include:
• Coverage. While coverage of health services differs from country to country, all countries need a structure to assure use of HTA in coverage decisions, even if they do have a health service instead of an i nsurance system. • Planning and regulation. Regulation, especially regulation of numbers and placement of services, has an important role to play in assuring appropriate access without excessive services. National and r egional regulation can be based on HTA to a greater extent than they are. • Designing and organizing a system for coordination and co-operation. In sum, the activities described here are quite complex. There is a need for designing a system of co-ordination acceptable to all member states. The European Commission could give support to such system design and integration.
European co-ordination
The HTA-Europe project, as well as the EUR-ASSESS project, was aimed at improving coordination of HTA activities in the European Union. The main conclusion of this report is that it would be beneficial for the healthcare system of European Union countries for the European Commission to assist the establishment of a co-ordinating mechanism for HTA at the European level. 
